COVID-19 Spike Protein (Delta Variant) mRNA-LNP
The spike protein of COVID-19 is a glycoprotein that helps the virus attach to various surfaces in the built environment, increasing the potential for virus transmission. The best-known vaccines we use are the spike protein vaccines delivered via mRNA. While the role of vaccination in controlling outbreaks is undeniable, the recurring emergence of new variants of Covid-19, such as the Delta and Omicron variants, poses new challenges, particularly their rapid global spread. The Delta variant was first detected in India in December 2020 and spread around the world due to its increased transmissibility. Compared with wild-type COVID-19, the Delta variant contains 11 mutations in the S protein, including 9 mutations in the N-terminal domain and 2 mutations in the receptor-binding domain (RBD). This product is designed as a tool for the delivery and expression of full-length spike protein mRNA of COVID-19 Strain Delta for vaccine research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of the Delta spike protein mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The spike protein sequence of the Delta (B.1.617.2) strain consists of 1271 amino acids, and the GenPept accession number is QWX82474. The full-length amino acid sequence of this Spike mRNA-LNP product is available upon request.